Lenalidomide Exposed, Anti-CD38 MAb, Relapsed Refractory Multiple Myeloma (RRMM), Daratumumab+Pomalidomide+Dexamethasone (DPd), Phase 3, 1,2,3,>=4 prior line of therapy, Pomalidomide+Dexamethasone (Pd)
### Instruction:
Identify the study with the following condition. 
### Input:
Lenalidomide Exposed, Anti-CD38 MAb, Relapsed Refractory Multiple Myeloma (RRMM), Daratumumab+Pomalidomide+Dexamethasone (DPd), Phase 3, 1,2,3,>=4 prior line of therapy, Pomalidomide+Dexamethasone (Pd) 
### Output:
Popular Name is APOLLO, Study ID is NCT03180736